Itamar Shimrat - Cell Source CEO
| CLCS Stock | USD 0.40 0.01 2.44% |
CEO
Mr. Itamar Shimrat is Chief Executive Officer, Chief Financial Officer, Director of the Company. A Canadian businessman and a founding member of Cell Source. Since Cell Source Israel inception, Mr. Shimrat served as a Director, Chief Financial Officer and, in October 2013, he was appointed Chief Executive Officer. Previously, Mr. Shimrat served as an Executive Vice President and Division Head at First International Bank of Israel, where he founded and led the strategic planning function, including planning, strategy, strategic marketing branding and project management oversight functions. He led a successful rebranding and repositioning of the bank and during his tenure the bank ROE was doubled. Previously, Mr. Shimrat worked as an international management consultant, chiefly at McKinsey Co., and he led successful major profit improvement programs for top tier financial institutions including Barclays in England and the Commonwealth Bank of Australia. He began his management consulting career at Bain Company, where he participated in the development of a new global retail strategy for Citibank. He holds an MBA with Distinction from the Ivey Business School of the University of Western Ontario in Canada. since 2014.
| Age | 64 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 646 416 7896 |
| Web | https://www.cell-source.com |
Cell Source Management Efficiency
The company has return on total asset (ROA) of (3.7761) % which means that it has lost $3.7761 on every $100 spent on assets. This is way below average. Cell Source's management efficiency ratios could be used to measure how well Cell Source manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CEO Age | ||
| Marcio MBA | Praxis Precision Medicines | 46 | |
| Tiago MD | Pasithea Therapeutics Corp | 48 | |
| Gerald Bruce | Virpax Pharmaceuticals | 67 | |
| Stephen Stamp | Biodexa Pharmaceticals | 63 | |
| Jatinder Dhaliwal | Virpax Pharmaceuticals | 37 | |
| Gareth Sheridan | Nutriband Warrant | 35 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
Management Performance
| Return On Asset | -3.78 |
Cell Source Leadership Team
Elected by the shareholders, the Cell Source's board of directors comprises two types of representatives: Cell Source inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cell. The board's role is to monitor Cell Source's management team and ensure that shareholders' interests are well served. Cell Source's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cell Source's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itamar Shimrat, CEO and President CFO, Principal Accounting Officer and Director | ||
| BSc MA, Ex Chairman |
Cell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cell Source a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.